Adverse Effects Associated With Newer Diabetes Therapies (Q38546214)

4 September 2017

1 reference

title

Adverse Effects Associated With Newer Diabetes Therapies (English)

1 reference

4 September 2017

Oluwaranti F Akiyode

1

1 reference

4 September 2017

Adebola A Adesoye

series ordinal

2

1 reference

4 September 2017

publication date

12 July 2015

1 reference

Journal of Pharmacy Practice

4 September 2017

published in

1 reference

4 September 2017

volume

30

1 reference

4 September 2017

issue

2

1 reference

4 September 2017

page(s)

238-244

1 reference

A review of the efficacy and safety of oral antidiabetic drugs

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Impact of GLP-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: a mixed treatment comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Clinical practice. Diabetic gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Do GLP-1-based therapies increase cancer risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

American College of Gastroenterology guideline: management of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Update on Safety Issues Related to Antihyperglycemic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

SGLT-2 Inhibitors: A New Mechanism for Glycemic Control

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial: Design and Methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190015594732

21 January 2018

Identifiers

DOI

10.1177/0897190015594732

1 reference

4 September 2017

1 reference